Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.09Last Year’s EPS
0.39Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 10, 2025
|% Change Since: -11.48%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, successful international launches, and strong financial management. However, increased operating expenses and challenges in awareness and adoption of PEDMARK, particularly in the AYA segment, were noted.Company Guidance
During Fennec Pharmaceuticals' fourth quarter and full year 2024 earnings call, the company provided guidance indicating a strong growth trajectory for 2025, driven by the PEDMARK strategy to address cisplatin-induced ototoxicity (CIO). Key metrics shared included a 40% revenue growth in 2024, with $29.6 million in net product sales, and a cash burn of only $0.6 million in Q4 2024. The company highlighted the expansion of PEDMARK's market, targeting the adolescent and young adult (AYA) segment, which represents approximately 20,000 cisplatin patients annually in the U.S., and has a favorable reimbursement profile. The product has been integrated into treatment plans at major centers like UCLA and Mount Sinai, signaling broader market acceptance. Internationally, Fennec initiated PEDMARQSI sales in the UK and Germany, with prices set at £8,277 and over €10,500 per vial, respectively. The company anticipates a decision on expanding PEDMARK's NCCN guidelines by mid-2025, which could further boost access and reimbursement pathways. Additionally, the company reported its cash position at $26.6 million by the end of 2024, following a $13 million debt repayment, and outlined expectations for operating expenses to remain similar in 2025, focusing on increased marketing and headcount to support growth.Significant Revenue Growth
Fennec Pharmaceuticals grew revenues by approximately 40% year-over-year, reaching $29.6 million in net product sales for fiscal year 2024, compared to $21.3 million in 2023.
PEDMARK Market Expansion
PEDMARK is gaining traction in select major academic centers across the U.S. and expanding into the adolescent and young adult (AYA) segment, with institutions such as UCLA, Fred Hutchinson Cancer Center, Mount Sinai, and Henry Ford Cancer Institute integrating PEDMARK into their treatment plans.
International Launch Success
The commercial launch of PEDMARQSI in Germany and the U.K. has been successful with promising initial revenue streams expected. The U.K. set a list price of £8277, and Germany's public price is more than €10,500 per vial.
Strong Financial Position
Cash and cash equivalents were $26.6 million as of December 31, 2024, with a strategic early repayment of $13 million of the Company's convertible debt, saving approximately $1.5 million in future annual interest payments.
---
FENC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FENC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 10, 2025 | $6.88 | $6.11 | -11.19% |
| Nov 07, 2024 | $4.95 | $4.36 | -11.92% |
| Aug 13, 2024 | $6.25 | $5.85 | -6.40% |
| May 14, 2024 | $10.02 | $7.34 | -26.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fennec Pharmaceuticals (FENC) report earnings?
Fennec Pharmaceuticals (FENC) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Fennec Pharmaceuticals (FENC) earnings time?
Fennec Pharmaceuticals (FENC) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FENC EPS forecast?
FENC EPS forecast for the fiscal quarter 2025 (Q1) is -0.09.
---